The aim of this study was to apply individualized, physiologically based pharmacokinetic modeling of CO production rates (iPBPK-R) measured by the erythromycin breath test to characterize the effect of hemodialysis on the function of nonrenal clearance pathways in patients with end-stage renal disease. Twelve patients previously received C-erythromycin intravenously pre- and post-hemodialysis. Serial breath samples were collected after each dose over 2 hours. Eight PBPK parameters were co-estimated across periods, whereas activity of cytochrome P450 (CYP) 3A4 clearance was independently estimated for each period. Inhibition coefficients for organic anion transporting polypeptide (OATP), P-glycoprotein, and multidrug resistance-associated protein 2 activities were also estimated. Nonrenal clearance parameter estimates were explored regarding sex differences and correlations with uremic toxins and were used in hierarchical cluster analysis (HCA). Relationships between the function of nonrenal clearance pathways and uremic toxin concentrations were explored. Mean CYP 3A4 clearance increased by 2.2% post-hemodialysis. Uptake transporter activity was highly intervariable across hemodialysis. Females had 22% and 30% higher median CYP3A4 activity than males pre- and post-hemodialysis, respectively. Exploratory HCA indicated that using both CYP3A4 and OATP activity parameters at pre- and post-hemodialysis best identifies heterogeneous patients. This is the first study to use the iPBPK-R approach to simultaneously estimate multiple in vivo nonrenal elimination pathways in individual patients with kidney disease and to assess the effect of hemodialysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jcph.1818 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatoprotective Effects of Resveratrol on Acetaminophen-Induced Acute Liver Injury and Its Implications for Tofacitinib Disposition in Rats.
Biomol Ther (Seoul)
December 2024
College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
Tofacitinib, which is used to treat rheumatoid arthritis (RA), is primarily metabolized by the hepatic cytochrome P450 (CYP) enzymes, CYP3A1/2 and CYP2C11. Acetaminophen (APAP), which is frequently used for pain relief in patients with RA, can induce acute liver injury (ALI) when taken in excess, profoundly affecting drug metabolism. Resveratrol (RVT) is a polyphenolic compound with hepatoprotective properties.
View Article and Find Full Text PDFPopulation pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant.
Clin Transl Sci
December 2024
Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, Funabashi, Chiba, Japan.
Article Synopsis
- The study developed a population pharmacokinetic (popPK) model to understand the complex absorption and variability of mycophenolic acid (MPA) in patients who have undergone renal transplantation.
- Nonlinear mixed-effects modeling was used to analyze data from 42 patients, resulting in a two-compartment model that factors in various influences like total body weight, renal function, and the days since transplantation.
- The simulation suggests that a dose of 500-1000 mg of MPA twice daily is recommended initially post-transplant, but adjustments may be needed as patients progress in their recovery or if renal function changes.
Population pharmacokinetic analysis in children with different diseases treated with mycophenolate mofetil-Integrated analysis of clinical trials and real-world clinical data.
Eur J Pharm Sci
January 2025
Department of Research and Development Supervision, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan. Electronic address:
Article Synopsis
- The study develops a population pharmacokinetic (PK) model of mycophenolic acid (MPA) specifically for pediatric patients with various diseases, using electronic medical records and previous pharmacokinetic studies.
- A non-linear mixed-effects modeling approach was utilized to estimate key PK parameters such as apparent clearance and volume of distribution while considering patient backgrounds and other variables.
- Analysis of data from 249 patients led to a two-compartment model showing a nonlinear relationship between dosage and MPA exposure, with specific PK parameters estimated for different patient groups.
Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data.
Antimicrob Agents Chemother
November 2024
Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Article Synopsis
- Sulbactam-durlobactam is a newly approved combination drug for treating specific types of pneumonia in adults, using data from multiple clinical studies to assess its pharmacokinetics.
- A complex four-compartment model was created to understand how the drug behaves in the body, factoring in both kidney and non-kidney clearance methods.
- Key findings showed that factors like body weight and renal function impact drug clearance, with the model being suitable for predicting how the drug performs in different patient populations.
Prediction of tissue exposures of polymyxin-B, amikacin and sulbactam using physiologically-based pharmacokinetic modeling.
Front Microbiol
October 2024
Department of Statistics, Universidade Estadual de Maringá, Maringá, Paraná, Brazil.
Background: The combination antimicrobial therapy consisting of amikacin, polymyxin-B, and sulbactam demonstrated synergy against multi-drug resistant .
Objectives: The objectives were to predict drug disposition and extrapolate their efficacy in the blood, lung, heart, muscle and skin tissues using a physiologically-based pharmacokinetic (PBPK) modeling approach and to evaluate achievement of target pharmacodynamic (PD) indices against .
Methods: A PBPK model was initially developed for amikacin, polymyxin-B, and sulbactam in adult subjects, and then scaled to pediatrics, accounting for both renal and non-renal clearances.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!